| Lewicka et al.[77 Lewicka E, Dudzińska-Gehrmann J, Dąbrowska-Kugacka A, Zagożdżon P, Stepnowska E, Liżewska A, et al. Plasma biomarkers as predictors of recurrence of atrial fibrillation. Pol Arch Med Wewn. 2015;125(6):424-33.]
|
preserved LVEF 55±5% |
median 51 days |
52 |
92% |
12 months |
pacemaker logs |
BNP |
| Andersson et al.[88 Andersson J, Rosenqvist M, Tornvall P, Boman K. NT-proBNP predicts maintenance of sinus rhythm after electrical cardioversion. Thromb Res. 2015;135(2):289-91.]
|
10% patients with heart failure |
>7 days |
199 |
54% |
1 month |
ECG |
NT-proBNP |
| Mukherjee et al.[99 Mukherjee R, Akar JG, Wharton JM, Adams DK, McClure CD, Stroud RE, et al. Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013;6(4):528-35.]
|
preserved LVEF 56.78±140.6% |
<1 year |
82 |
44% |
12±2 weeks |
Physical, ECG |
NT-proBNP |
| Govindan et al.[1010 Govindan M, Borgulya G, Kiotsekoglou A, Saha SK, Camm AJ. Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence. Europace. 2012;14(9):1302-10.]
|
preserved LVEF>50% |
<18 months |
54 |
61% |
12 months |
Holter, ECG, physical |
NT-proBNP |
| Kawamura et al.[1111 Kawamura M, Munetsugu Y, Kawasaki S, Onishi K, Onuma Y, Kikuchi M, et al. Type III procollagen-N-peptide as a predictor of persistent atrial fibrillation recurrence after cardioversion. Europace. 2012;14(12):1719-25.]
|
preserved LVEF 61.1±9.6% |
37±26 days |
142 |
38% |
24 months |
ECG |
BNP |
| Barassi et al.[1212 Barassi A, Pezzilli R, Morselli-Labate AM, Lombardi F, Belletti S, Dogliotti G, et al. Serum amyloid and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol. 2012;28(5):537-41.]
|
preserved LVEF 58.7±6% |
3 months |
57 |
33% |
3 weeks |
ECG |
BNP |
| Falcone et al.[1313 Falcone C, Buzzi MP, D'Angelo A, Schirinzi S, Falcone R, Rordorf R, et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol. 2010;23(3):917-25.]
|
NYHA I or II |
93±65 days |
93 |
28% |
6 months |
Holter, ECG |
BNP |
| Wozakowska-Kaplon et al.[1414 Wozakowska-Kapłon B, Bartkowiak R, Grabowska U, Janiszewska G. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation - clinical significance. Kardiol Pol. 2010;68(7):781-6.]
|
NYHA I, LVEF 58.1±6.4 % |
>48 hours, <12 months |
77 |
39% |
6 months |
ECG, Holter |
BNP |
| Kallergis et al.[1515 Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Goudis CA, Maliaraki NE, et al. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation. Am J Cardiol. 2010;105(1):90-4.]
|
LVEF 57.1± 8.5% |
>3 months |
40 |
23% |
1 month |
ECG |
NT-proBNP |
| Ari et al.[1616 Ari H, Binici S, Ari S, Akkaya M, Koca V, Bozat T, et al. The predictive value of plasma brain natriuretic peptide for the recurrence of atrial fibrillation six months after external cardioversion. Turk Kardiyol Dern Ars. 2008;36(7):456-60.]
|
preserved LVEF 55.5±2.98% |
23.2±6.5 months |
58 |
34.5% |
6 months |
ECG |
BNP |
| Mollmann et al.[1717 Möllmann H, Weber M, Elsässer A, Nef H, Dill T, Rixe J, et al. NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J. 2008;72(6):921-5.]
|
LVEF >45% |
181.5±327days |
49 |
36% |
4 weeks |
Holter, ECG |
NT-proBNP |
| Lombardi et al.[1818 Lombardi F, Tundo F, Belletti S, Mantero A, Melzi D'eril GV. C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. J Cardiovasc Med (Hagerstown). 2008;9(6):581-8.]
|
LVEF >45% |
1 month-1 year |
53 |
34% |
3 weeks |
Holter, ECG |
NT-proBNP |
| Tveit et al.[1919 Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Arnesen H, Smith P. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol. 2009;131(2:234-9).]
|
NHYA I |
median 10.5 weeks |
129 |
69% |
6 months |
ECG |
NT-proBNP |
| Buob et al.[2020 Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol. 2006;29(6):559-63.]
|
LVEF 57±11% |
90±75 days |
25 |
44% |
4 weeks |
Physical, ECG |
NT-proBNP |
| Shin et al.[2121 Shin DI, Jaekel K, Schley P, Sause A, Müller M, Fueth R, et al. Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol. 2005;94(12):795-800.]
|
normal LVEF |
10.9±8.3 weeks |
34 |
29.4% |
11 days |
ECG |
NT-proBNP |
| Lellouche et al.[2222 Lellouche N, Berthier R, Mekontso-Dessap A, Braconnier F, Monin JL, Duval AM, et al. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol. 2005;95(11):1380-2.]
|
NYHA I or II |
3.7 months |
66 |
45% |
1 year |
ECG |
BNP |
| Mabuchi et al.[2323 Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J. 2000;64(10):765-71.]
|
NYHA II or III |
mean 5.8 months |
65 |
45% |
553 days |
Physical, ECG |
BNP |
| Beck-da-Silva et al.[2424 Beck-da-Silva L, Bold A, Fraser M, Williams K, Haddad H. Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Can J Cardiol. 2004;20(12):1245-8.]
|
NYHA I or II, preserved LVEF |
6 months |
14 |
36% |
2 weeks |
ECG |
BNP |
| Watanabe et al.[2525 Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol. 2006;108(3):346-53.]
|
NYHA I -III, LVEF 59±10% |
(1-350) days |
84 |
76% |
12 months |
Holter, ECG |
BNP |
